The global knee hyaluronic acid injections market is experiencing significant growth due to the rising incidence of osteoarthritis (OA), an aging population, and increasing demand for non-surgical and minimally invasive treatment options. Hyaluronic acid injections, also known as viscosupplementation, are widely used to provide relief from knee pain caused by osteoarthritis. These injections improve joint function and lubrication, which helps patients delay or avoid the need for more invasive procedures such as knee replacement surgery. The market is witnessing advancements in HA formulations and delivery methods, creating new opportunities for manufacturers and healthcare providers.

Knee hyaluronic acid injections are a part of the broader viscosupplementation therapy that involves injecting a gel-like fluid containing hyaluronic acid directly into the knee joint. HA is a naturally occurring substance in the synovial fluid that lubricates the joint and acts as a shock absorber. In osteoarthritis, the concentration and molecular weight of HA are reduced, leading to joint pain and stiffness. Supplementing the joint with exogenous HA helps restore normal joint function and provides symptomatic relief.

The global knee HA injections market is projected to grow at a steady compound annual growth rate (CAGR) over the forecast period, driven by increasing awareness about non-surgical treatment options and a growing geriatric population susceptible to joint-related disorders.

Knee Hyaluronic Acid Injections Market exhibiting a compound annual growth rate (CAGR) of 5.17% during the forecast period (2025 - 2034).

Market Drivers

• Rising Prevalence of Osteoarthritis
  One of the primary factors fueling the growth of the knee HA injections market is the increasing prevalence of osteoarthritis, especially among the elderly. According to the Centers for Disease Control and Prevention (CDC), millions of adults in the U.S. alone suffer from osteoarthritis, with the knee being one of the most commonly affected joints. This creates a consistent and expanding patient base for hyaluronic acid injection treatments.
• Growing Geriatric Population
  The global population is aging at an unprecedented rate. As people age, their joints undergo wear and tear, increasing their vulnerability to degenerative joint diseases. The elderly often seek non-invasive and low-risk treatment alternatives, which increases the adoption of HA injections for knee osteoarthritis.
• Increasing Preference for Non-Surgical Treatments
  With the advancement of medical technology and patient preferences shifting toward minimally invasive procedures, HA injections are becoming a preferred treatment modality. They offer temporary pain relief, improved mobility, and delayed need for surgical intervention.
• Product Innovation and Advancements
  Manufacturers are continuously working on developing new and improved formulations with enhanced efficacy, longer duration of action, and fewer side effects. Cross-linked HA and high-molecular-weight HA formulations are among the innovations gaining popularity. Additionally, combination therapies with corticosteroids or platelet-rich plasma (PRP) are also being explored.

Key players in the Knee Hyaluronic Acid Injections Market include:

Geistlich Biomaterials, Hyalgan, Marker Therapeutics, Johnson Johnson, Fidia Farmaceutici, Orthogenix, DePuy Synthes, OssDsign, Stryker, Arthrex, Medtronic, Sanofi Aventis, Zimmer Biomet, Bioventus.

Market Restraints

• Limited Efficacy in Severe OA Cases
  While HA injections are effective in mild to moderate cases of osteoarthritis, their effectiveness in severe cases is often limited. Patients with advanced joint degeneration may require surgical interventions like total knee replacement, thereby reducing the addressable market for HA injections in such cases.
• Cost and Insurance Coverage Limitations
  Hyaluronic acid injections can be relatively expensive, and in some regions, insurance reimbursement for such treatments is limited or denied. This can be a barrier, especially for patients in developing economies with limited healthcare access.
• Regulatory and Clinical Challenges
  Regulatory restrictions and the need for robust clinical evidence on long-term effectiveness can hinder market growth. Additionally, guidelines from certain medical associations have questioned the cost-effectiveness of HA injections, which may influence prescribing patterns.

For More Information Request for Sample PDF

Recent Developments

• Companies have introduced combination therapies involving HA and corticosteroids to enhance pain relief.
• Bioventus and other firms have developed single-injection formats to cater to patient convenience.
• Regulatory approvals in emerging markets are paving the way for new entrants.

Contact Us:
Market Researcnh Future (Part of WantStats Research and Media Pvt. Ltd.)
Contact Number. +91 2269738890
Email: sales@marketresearchfuture.com